Cooperation between the Pharmaceutical Industry and Academic Institutions in Drug Discovery

2012 ◽  
pp. 529-544
Author(s):  
Valdir Cechinel-Filho ◽  
Rivaldo Niero ◽  
Rosendo A. Yunes
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Industry ◽  
Academic Institutions

Drug Discovery

2018 ◽  
pp. 399-404
Author(s):  
S. Nassir Ghaemi
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Industry ◽  
Discovery Process ◽  
Drug Discovery Process ◽  
New Approach ◽  
The Past ◽  
Scientific Exploration ◽  
Clinical Indications ◽  
The Future ◽  
Clinical Diagnoses

Newer and better medications are obtained as part of the drug discovery process, which occurs mainly in the pharmaceutical industry. This process is hampered by excessive attention to marketing demands, as opposed to scientific exploration. It also is impaired by the psychiatric profession’s mistaken ideologies, whether psychoanalytic orthodoxy in the past or DSM beliefs of the present. Wrong clinical phenotypes impair finding new pharmacological mechanisms and targeting them well to the write clinical indications. Perhaps as a consequence, no treatments have been developed in the last few decades, since DSM-III, that are more effective than prior agents. Progress for the future in drug discovery will require not just better neurobiological work, but also a new approach to clinical diagnoses in psychiatry.

Industry–Academic Relationship in a New Era of Drug Discovery

2016 ◽  
Vol 34 (29) ◽  
pp. 3570-3575 ◽  
Author(s):  
Patrick Vallance
Keyword(s):  
Drug Discovery ◽  
Career Development ◽  
Pharmaceutical Industry ◽  
Target Identification ◽  
Human Biology ◽  
Experimental Medicine ◽  
Clinical Testing ◽  
New Era ◽  
Academic Partnerships ◽  
The Relationship

The pharmaceutical industry is entering a renewed period of productivity as a result of advances in the understanding of human biology, particularly in the areas of genetics and immunology. The relationship between industry and academia needs to evolve to maximize the opportunity. In four areas—target identification, the molecule itself, experimental medicine, and larger-scale clinical testing—there are specific needs for academic partnerships that should be open and transparent and include talent, skills, and career development.

Making medicines

2018 ◽  
Vol 32 (5) ◽  
pp. 302-311 ◽  
Author(s):  
Elizabeth K. McClain ◽  
Yolanda Johnson-Moton ◽  
Bryan Larsen ◽  
Rebecca J. Bartlett Ellis ◽  
Eric Niederhoffer
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Industry ◽  
Development Process ◽  
Course Development ◽  
Educational Partnerships ◽  
Collaborative Process ◽  
Drug Discovery And Development ◽  
Online Module ◽  
Systems Thinking Approach

The approach to building innovative partnerships between academia and the pharmaceutical industry has expanded to investigate collaborations that offer meaningful outcomes beyond discovery and increased productivity. This case study uses a systems thinking approach to guide the process and analyse the outcome of a partnership undertaken by one pharmaceutical company and academia. The collaborative process established three tiers of evolution over a 3-year period. The outcome was an online module–based course, entitled ‘Making Medicines: The Process of Drug Development’, that provides information about the drug discovery and development process. Both the course development and the final product serve as a useful case study of how collaboration between academia and industry might be achieved. The development process itself is proposed as an appropriate approach for building educational partnerships.

scholarly journals An expanding role for cell biologists in drug discovery and pharmacology

2012 ◽  
Vol 23 (21) ◽  
pp. 4162-4164 ◽  
Author(s):  
Peter K. Sorger ◽  
Birgit Schoeberl
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Industry ◽  
Drug Development ◽  
Basic Structure ◽  
Healthcare Systems ◽  
New Drugs ◽  
Conceptual Basis ◽  
The Face ◽  
Programming Skills ◽  
In Cells

The profound challenges facing clinicians, who must prescribe drugs in the face of dramatic variability in response, and the pharmaceutical industry, which must develop new drugs despite ever-rising costs, represent opportunities for cell biologists interested in rethinking the conceptual basis of pharmacology and drug discovery. Much better understanding is required of the quantitative behaviors of networks targeted by drugs in cells, tissues, and organisms. Cell biologists interested in these topics should learn more about the basic structure of drug development campaigns and hone their quantitative and programming skills. A world of conceptual challenges and engaging industry–academic collaborations awaits, all with the promise of delivering real benefit to patients and strained healthcare systems.

The impact of biotechnology and molecular biology on the pharmaceutical industry

1992 ◽  
Vol 99 (1-2) ◽  
pp. 37-45
Author(s):  
A. N. Hobden ◽  
T. J. R. Harris
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Industry ◽  
Protein Function ◽  
High Throughput Screening ◽  
Mammalian Cells ◽  
Recombinant Dna ◽  
Hiv Protease ◽  
Baculovirus Infection ◽  
Recombinant Dna Techniques ◽  
The Impact

Synopsis:Biotechnology had its initial impact on the pharmaceutical industry well before the perceived time. The use of fermentation technology to produce antibiotics was a cornerstone for the development of the industry. This event was both before cloning (BC) and before DNA (rather than after DNA – AD). Even now the antibiotic market, which is worth over 10 billion U.S. dollars a year, is the most valuable segment of the total market, (c.200 billion dollars per year). Nevertheless the impact of biotechnology in drug discovery was until recently perceived solely to be the use of recombinant DNA techniques to produce therapeutic proteins and modified versions of them by protein engineering.There are several other places where genetic engineering is influencing drug discovery. The expression of recombinant proteins in surrogate systems (e.g. in E. coli, yeast or via baculovirus infection or in mammalian cells) provides materials for structure determination (e.g. HIV protease) and structure/function studies (e.g. various receptors). Recombinant DNA techniques are influencing assay technology by allowing access to proteins in sufficient quantity for high throughput screening.In addition, screening organisms can be constructed where a particular protein function can be measured in a microorganism by complementation or via reporter gene expression.Transgenic animals also illustrate the power of the technology for drug discovery. Not only will transgenic rats and mice be used as models of disease but also for efficacy and toxicological profiling. What is learned in transgenic rodents may well set the scene for somatic cell gene therapy in humans.

Sign in / Sign up

Export Citation Format

Share Document